The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Genpact's revenues will grow 13.9% and EPS will wane -7.4%.
The average estimate for revenue is $532.7 million. On the bottom line, the average EPS estimate is $0.25.
Last quarter, Genpact chalked up revenue of $503.8 million. GAAP reported sales were 16% higher than the prior-year quarter's $435.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $0.23. GAAP EPS of $0.20 for Q1 were 18% higher than the prior-year quarter's $0.17 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 38.1%, 90 basis points worse than the prior-year quarter. Operating margin was 14.7%, 70 basis points better than the prior-year quarter. Net margin was 9.3%, 40 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.19 billion. The average EPS estimate is $1.01.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 119 members out of 143 rating the stock outperform, and 24 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Genpact a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Genpact is outperform, with an average price target of $18.47.
Is Genpact playing the right part in the new technology revolution? Computers, mobile devices, and related services are creating huge amounts of valuable data, but only for companies that can crunch the numbers and make sense of it. Meet the leader in this field in "The Only Stock You Need To Profit From the NEW Technology Revolution." Click here for instant access to this free report.
- Add Genpact to My Watchlist.